Cover Image

Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study

Understanding the impact of the tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors may help optimize both patient and treatment selection in metastatic triple-negative breast cancer. In this substudy from the phase 3 IMp...

Full description

Saved in:
Bibliographic Details
Main Authors: Emens, Leisha Ann (Author) , Molinero, Luciana (Author) , Loi, Sherene (Author) , Rugo, Hope S (Author) , Schneeweiss, Andreas (Author) , Diéras, Véronique (Author) , Iwata, Hiroji (Author) , Barrios, Carlos H (Author) , Nechaeva, Marina (Author) , Nguyen-Duc, Anh (Author) , Chui, Stephen Y (Author) , Husain, Amreen (Author) , Winer, Eric P (Author) , Adams, Sylvia (Author) , Schmid, Peter (Author)
Format: Article (Journal)
Language:English
Published: 01 February 2021
In: Journal of the National Cancer Institute
Year: 2021, Volume: 113, Issue: 8, Pages: 1005-1016
ISSN:1460-2105
DOI:10.1093/jnci/djab004
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/jnci/djab004
Get full text
Author Notes:Leisha A. Emens, MD, PhD, Luciana Molinero, PhD, Sherene Loi, MD, PhD, Hope S. Rugo, MD, Andreas Schneeweiss, MD, Véronique Diéras, MD, Hiroji Iwata, MD, PhD, Carlos H. Barrios, MD, Marina Nechaeva, MD, Anh Nguyen-Duc, PhD, Stephen Y. Chui, MD, Amreen Husain, MD, Eric P. Winer, MD, Sylvia Adams, MD, Peter Schmid, MD, PhD
Description
Summary:Understanding the impact of the tumor immune microenvironment and BRCA1/2-related DNA repair deficiencies on the clinical activity of immune checkpoint inhibitors may help optimize both patient and treatment selection in metastatic triple-negative breast cancer. In this substudy from the phase 3 IMpassion130 trial, immune biomarkers and BRCA1/2 alterations were evaluated for association with clinical benefit with atezolizumab and nab-paclitaxel (A+nP) vs placebo and nP in unresectable (P+nP) locally advanced or metastatic triple-negative breast cancer.Patients were randomly assigned 1:1 to nab-paclitaxel 100 mg/m2 (days 1, 8, and 15 of a 28-day cycle) and atezolizumab 840 mg every 2 weeks or placebo until progression or toxicity. Progression-free survival and overall survival were evaluated based on programmed death-ligand 1 (PD-L1) expression on immune cells (IC) and tumor cells, intratumoral CD8, stromal tumor-infiltrating lymphocytes, and BRCA1/2 mutations.PD-L1 IC+ in either primary or metastatic tumor tissue was linked to progression-free survival and overall survival benefit with A+nP. PD-L1 IC+ low (26.9%; 243 of 902 patients) and high (13.9%; 125 of 902 patients) populations had improved outcomes that were comparable. Intratumoral CD8 and stromal tumor-infiltrating lymphocytes positivity (sTIL+) were associated with PD-L1 IC+ status; improved outcomes were observed with A+nP vs P+nP only in CD8+ and sTIL+ patients who were also PD-L1 IC+. BRCA1/2 mutations (occurring in 14.5% [89 of 612 patients]) were not associated with PD-L1 IC status, and PD-L1 IC+ patients benefited from A+nP regardless of BRCA1/2 mutation status.Although A+nP was more efficacious in patients with richer tumor immune microenvironment, clinical benefit was only observed in patients whose tumors were PD-L1 IC+.
Item Description:Gesehen am 09.12.2021
Physical Description:Online Resource
ISSN:1460-2105
DOI:10.1093/jnci/djab004

Similar Items